Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells

Tuba TÜYLÜ KÜÇÜKKILINÇ (Hacettepe Üniversitesi, Eczacılık Fakültesi, Biyokimya Anabilim Dalı, Ankara, Türkiye)
Journal of research in pharmacy (online)
1 0
Yıl: 2022 Cilt: 26 Sayı: 2 Sayfa Aralığı: 362 - 369 Metin Dili: İngilizce DOI: 10.29228/jrp.134 İndeks Tarihi: 07-06-2022

Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells

Öz:
Anti-hormone therapy mediated cognitive decline among cancer patients has been referred to as chemobrain. Current literature indicates that declined estrogen in the brain may be contributing to the genesis of this phenomenon. Aromatase is a key enzyme that converts C19 steroids to estrogen in the brain, although its involvement in cognitive function has remained obscure. This study evaluated the downregulation of aromatase by siRNA treatment and the effect of aromatase downregulation on mRNA expression and specific activity of acetylcholinesterase in SHSY5Y cells. short interfering RNA duplexes were employed to achieve aromatase gene downregulation in SH-SY5Y cells. The reduction of aromatase mRNA was analyzed by real-time PCR. Estradiol levels were determined to confirm the downregulation by a commercial ELISA kit. Acetylcholinesterase mRNA level of siRNA-treated SH-SY5Y cells was analyzed employing Real-time PCR. Specific acetylcholinesterase activity was determined using the Ellman method. Viability and caspase 3/7 activity was examined using ApoTox-GloTM Triplex Assay. zVad-Fmk was employed as a pan-caspase inhibitor in experimental groups.Real-time PCR analysis showed a significant decrease in aromatase mRNA. The downregulation data was also confirmed using an ELISA estradiol kit. Acetylcholinesterase mRNA level was determined significantly reduced in siRNA-treated SH-SY5Y cells. It was observed that the specific activity of acetylcholinesterase was also reduced. Aromatase downregulation didn’t alter viability or caspase 3/7 activity of SHSY5Y cells. However, aromatase downregulation increased susceptibility to caspase-dependent apoptosis.Considering our findings, there may be interactions between aromatase and acetylcholinesterase that have not yet been elucidated and may contribute to the mechanism of chemobrain.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1] Henderson VW. Cognitive Changes After Menopause: Influence of Estrogen. Clin Obstet Gynecol. 2008; 51(3): 618-626. [CrossRef]
  • [2] Rao SM, Malkin MG, Durgerian S, Restrepo JA, Pezzin LE, Nattinger AB. Cognitive Performance among Breast Cancer Survivors Treated with Aromatase Inhibitors. J Cancer Res Ther. 2013; 2(1): 1-7. [CrossRef]
  • [3] Phillips KA, Ribi K, Fisher R. Do aromatase inhibitors have adverse effects on cognitive function? Breast Cancer Res. 2011; 13(1): 203. [CrossRef]
  • [4] Li R, Cui J, Shen Y. Brain sex matters: estrogen in cognition and Alzheimer's disease. Mol Cell Endocrinol. 2014; 389(1- 2): 13-21. [CrossRef]
  • [5] Contestabile A. The history of the cholinergic hypothesis. Behav Brain Res. 2011; 221(2): 334-340. [CrossRef]
  • [6] Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg. 1999; 66(2): 137-147. [CrossRef]
  • [7] Bartus R, Dean R, Beer B, Lippa A. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982; 217(4558): 408-414. [CrossRef]
  • [8] Terry AV, Buccafusco JJ. The Cholinergic Hypothesis of Age and Alzheimers Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development. J Pharmacol Exp Ther. 2003; 306(3): 821-827.[CrossRef]
  • [9] Shughrue PJ, Scrimo PJ, Merchenthaler I. Estrogen binding and estrogen receptor characterization (ERα and ERβ) in the cholinergic neurons of the rat basal forebrain. Neuroscience. 2000; 96(1): 41-49.[CrossRef]
  • [10] Abraham IM, Koszegi Z, Tolod-Kemp E, Szego EM. Action of estrogen on survival of basal forebrain cholinergic neurons: promoting amelioration. Psychoneuroendocrinology. 2009; 34 Suppl 1: S104-112.[CrossRef]
  • [11] García-Ayllón M-S, Small DH, Avila J, Sáez-Valero J. Revisiting the Role of Acetylcholinesterase in Alzheimer’s Disease: Cross-Talk with P-tau and β-Amyloid. Front Mol Neurosci. 2011; 4: 22.[CrossRef]
  • [12] Grisaru D, Lev-Lehman E, Shapira M, Chaikin E, Lessing JB, Eldor A, Eckstein F, Soreq H. Human Osteogenesis Involves Differentiation-Dependent Increases in the Morphogenically Active 3′ Alternative Splicing Variant of Acetylcholinesterase. Mol Cell Biol. 1999; 19(1): 788-795.[CrossRef]
  • [13] Luine VN, Rhodes JC. Gonadal hormone regulation of MAO and other enzymes in hypothalamic areas. Neuroendocrinology. 1983; 36(3): 235-241.[CrossRef]
  • [14] Degano B, Prévost M-C, Berger P, Molimard M, Pontier S, Rami J, Escamilla R. Estradiol Decreases the Acetylcholineelicited Airway Reactivity in Ovariectomized Rats through an Increase in Epithelial Acetylcholinesterase Activity. Am J Respir Crit Care Med. 2001; 164(10): 1849-1854.[CrossRef]
  • [15] Abdul-Karim RW, Drucker M, Jacobs RD. The influence of estradiol-17β on cholinesterase activity in the lung. Am J Obstet Gynecol. 1970; 108(7): 1098-1101.[CrossRef]
  • [16] Hervonen A, Kanerva L, Lietzén R. Histochemically Demonstrable Catecholamines and Cholinesterases of the Rat Uterus during Estrus Cycle, Pregnancy and after Estrogen Treatment. Acta Physiol Scand. 1973; 87(2): 283-288.[CrossRef]
  • [17] Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP. Either called "chemobrain" or "chemofog," the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manag. 2011; 41(1): 126-139.[CrossRef]
  • [18] Shilling V, Jenkins V, Fallowfield L, Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol. 2003; 86(3-5): 405-412.[CrossRef]
  • [19] Rosenfeld CS, Shay DA, Vieira-Potter VJ. Cognitive effects of aromatase and possible role in memory disorders. Front Endocrinol. 2018; 9: 610.[CrossRef]
  • [20] Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 1996; 46(6): 1580-1584.[CrossRef]
  • [21] Gibbs RB, Chipman AM, Nelson D. Donepezil plus estradiol treatment enhances learning and delay-dependent memory performance by young ovariectomized rats with partial loss of septal cholinergic neurons. Horm Behav. 2011; 59(4): 503-511.[CrossRef]
  • [22] Li J, Rao D, Gibbs RB. Effects of Cholinergic Lesions and Cholinesterase Inhibitors on Aromatase and Estrogen Receptor Expression in Different Regions of the Rat Brain. Neuroscience. 2018; 384: 203-213.[CrossRef]
  • [23] Azcoitia I, Sierra A, Veiga S, Honda S, Harada N, Garcia-Segura LM. Brain aromatase is neuroprotective. J Neurobiol. 2001; 47(4): 318-329.[CrossRef]
  • [24] Garcia-Segura LM, Veiga S, Sierra A, Melcangi RC, Azcoitia I. Aromatase: a neuroprotective enzyme. Prog Neurobiol. 2003; 71(1): 31-41.[CrossRef]
  • [25] Amantea D, Russo R, Bagetta G, Corasaniti MT. From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens. Pharmacol Res. 2005; 52(2): 119-132.[CrossRef]
  • [26] Thiantanawat A, Long BJ, Brodie AM. Signaling Pathways of Apoptosis Activated by Aromatase Inhibitors and Antiestrogens. Cancer Res. 2003; 63(22): 8037-8050.[CrossRef]
  • [27] Daniel JM, Fader AJ, Spencer AL, Dohanich GP. Estrogen Enhances Performance of Female Rats during Acquisition of a Radial Arm Maze. Horm Behav. 1997; 32(3): 217-225.[CrossRef]
  • [28] Luine VN, Jacome LF, Maclusky NJ. Rapid enhancement of visual and place memory by estrogens in rats. Endocrinology. 2003; 144(7): 2836-2844.[CrossRef]
  • [29] Sherwin BB, Henry JF. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Front Neuroendocrinol. 2008; 29(1): 88-113.[CrossRef]
  • [30] Roselli CF. Brain aromatase: roles in reproduction and neuroprotection. J Steroid Biochem Mol. 2007; 106(1-5): 143- 150.[CrossRef]
  • [31] Gallicchio L, Calhoun C, Helzlsouer K. A prospective study of aromatase inhibitor therapy initiation and self-reported side effects. Support Care Cancer. 2017; 25(9): 2697-2705.[CrossRef]
  • [32] Le Rhun E, Delbeuck X, Lefeuvre-Plesse C, Kramar A, Skrobala E, Pasquier F, Bonneterre J. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Breast Cancer Res Treat. 2015; 152(3): 569-580.[CrossRef]
  • [33] Gibbs RB. Effects of gonadal hormone replacement on measures of basal forebrain cholinergic function. Neuroscience. 2000; 101(4): 931-938.[CrossRef]
  • [34] Gabor R, Nagle R, Johnson DA, Gibbs RB. Estrogen enhances potassium-stimulated acetylcholine release in the rat hippocampus. Brain Res. 2003; 962(1-2): 244-247.[CrossRef]
  • [35] Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, Kilbourn MR. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology. 1999; 52(4): 691-699.[CrossRef]
  • [36] Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. Jama. 1999; 281(15): 1401-1406.[CrossRef]
  • [37] Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, Ota T, Tanada S, Irie T. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol. 2000; 48(2): 194-200.[CrossRef]
  • [38] Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, Tanada S, Irie T. Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography. Alzheimer Dis Assoc Disord. 2000; 14 Suppl 1: S114-118.[CrossRef]
  • [39] Liao K-F, Lin C-L, Lai S-W. Nationwide Case-Control Study Examining the Association between Tamoxifen Use and Alzheimer’s Disease in Aged Women with Breast Cancer in Taiwan. Front Pharmacol. 2017; 8(612).[CrossRef]
  • [40] Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res. 2003; 63(22): 8037-8050.[CrossRef]
  • [41] Williams MM, Lee L, Werfel T, Joly MMM, Hicks DJ, Rahman B, Elion D, McKernan C, Sanchez V, Estrada MV, Massarweh S, Elledge R, Duvall C, Cook RS. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis. 2018; 9(2): 21.[CrossRef]
  • [42] Rozeboom B, Dey N, De P. ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. Am J Cancer Res. 2019; 9(12): 2821-2831.[CrossRef]
  • [43] Misaghi S, Korbel GA, Kessler B, Spooner E, Ploegh HL. z-VAD-fmk inhibits peptide:N-glycanase and may result in ER stress. Cell Death Differ. 2006; 13(1): 163-165.[CrossRef]
  • [44] Schotte P, Declercq W, Van Huffel S, Vandenabeele P, Beyaert R. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS letters. 1999; 442(1): 117-121.[CrossRef]
  • [45] Kennedy NJ, Kataoka T, Tschopp J, Budd RC. Caspase activation is required for T cell proliferation. J Exp Med. 1999; 190(12): 1891-1896.[CrossRef]
  • [46] Lawrence CP, Chow SC. Suppression of human T cell proliferation by the caspase inhibitors, z-VAD-FMK and z-IETDFMK is independent of their caspase inhibition properties. Toxicol Appl Pharmacol. 2012; 265(1): 103-112. [CrossRef]
  • [47] Cepa M, Correia-da-Silva G, da Silva EJT, Roleira FM, Borges M, Teixeira NA. New steroidal aromatase inhibitors: Suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death. BMC Cell Biol. 2008; 9(1): 41.[CrossRef]
  • [48] Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961; 7(2): 88-95.[CrossRef]
  • [49] Ayazgök B, Tüylü Küçükkılınç T. Low-dose bisphenol A induces RIPK1-mediated necroptosis in SH-SY5Y cells: Effects on TNF-α and acetylcholinesterase. J Biochem Mol Toxicol. 2018: e22233.[CrossRef]
APA KÜÇÜKKILINÇ T (2022). Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells. , 362 - 369. 10.29228/jrp.134
Chicago KÜÇÜKKILINÇ Tuba Tüylü Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells. (2022): 362 - 369. 10.29228/jrp.134
MLA KÜÇÜKKILINÇ Tuba Tüylü Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells. , 2022, ss.362 - 369. 10.29228/jrp.134
AMA KÜÇÜKKILINÇ T Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells. . 2022; 362 - 369. 10.29228/jrp.134
Vancouver KÜÇÜKKILINÇ T Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells. . 2022; 362 - 369. 10.29228/jrp.134
IEEE KÜÇÜKKILINÇ T "Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells." , ss.362 - 369, 2022. 10.29228/jrp.134
ISNAD KÜÇÜKKILINÇ, Tuba Tüylü. "Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells". (2022), 362-369. https://doi.org/10.29228/jrp.134
APA KÜÇÜKKILINÇ T (2022). Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells. Journal of research in pharmacy (online), 26(2), 362 - 369. 10.29228/jrp.134
Chicago KÜÇÜKKILINÇ Tuba Tüylü Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells. Journal of research in pharmacy (online) 26, no.2 (2022): 362 - 369. 10.29228/jrp.134
MLA KÜÇÜKKILINÇ Tuba Tüylü Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells. Journal of research in pharmacy (online), vol.26, no.2, 2022, ss.362 - 369. 10.29228/jrp.134
AMA KÜÇÜKKILINÇ T Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells. Journal of research in pharmacy (online). 2022; 26(2): 362 - 369. 10.29228/jrp.134
Vancouver KÜÇÜKKILINÇ T Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells. Journal of research in pharmacy (online). 2022; 26(2): 362 - 369. 10.29228/jrp.134
IEEE KÜÇÜKKILINÇ T "Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells." Journal of research in pharmacy (online), 26, ss.362 - 369, 2022. 10.29228/jrp.134
ISNAD KÜÇÜKKILINÇ, Tuba Tüylü. "Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells". Journal of research in pharmacy (online) 26/2 (2022), 362-369. https://doi.org/10.29228/jrp.134
Sayfa Oluşturulma Tarihi
23-04-2024 22:54

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları